Susan earned widespread recognition as Chair of Shire plc (2014-2019), leading the £45 billion global pharmaceutical group through complex acquisition integration and its sale to Takeda. In her executive career, she held senior investment banking roles at Credit Suisse, including Head of EMEA M&A, and before that, at Bankers Trust, Barclays, and First Boston.

Her governance credentials span blue-chip global boards. She was Non-Executive Director at Goldman Sachs International (2016-2018), Keurig Green Mountain, Coca‑Cola HBC, L’Occitane, BHP Group, and BBA Aviation, frequently chairing remuneration and audit committees.

She brings deep cross-sector expertise in:

• M&A & integration leadership – steering high-value acquisitions and strategic exits in pharmaceuticals and consumer sectors

• Executive pay & audit governance – structuring incentive frameworks and audit oversight across global FTSE and NYSE companies

• Consumer & healthcare strategy – advising on capital and risk in diversified consumer and biopharma boards

• Board development & diversity advocacy – mentoring leaders and promoting gender balance through roles with C200 and Bayes Business School (formerly Cass)

Educated at Wellesley College (BA Economics) and Yale School of Management (MBA), Susan holds an honorary DSc from City University of London. Recognised by Forbes and Financial News as a top woman in finance, she is also a Senior Visiting Fellow at Bayes Business School and Chair of its M&A Research Centre.

Susan is admired for her sharp financial intellect, strategic discipline, and governance integrity—qualities that make her a powerful mentor for executives navigating M&A, board environments, and cross-border corporate transformations.